CGRP IN THE JOURNALS NICE rejects Aimovig (erenumab) use on NHS in England Eptinezumab is focus of planned Lundbeck takeover of Alder BioPharmaceuticals Migraine Awareness Week (1-7 September) – campaigning for change Tear fluid offers new insights to CGRP activity in patients with migraine Emgality (galcanezumab) effective in patients who failed previous preventive migraine therapies Wake up to World Brain Day – 22 July 2019 Rimegepant moves into trigeminal neuralgia trials

Partnership & Outreach

Through its unique global network of researchers and clinicians, the CGRP Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of the burden, disability and cost associated with migraine.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2019 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |

MENU